Free public records show Skyhawk Therapeutics, Inc. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Skyhawk Therapeutics, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
3 active studies led by Skyhawk Therapeutics, Inc., of 3 in all
Source: ClinicalTrials.gov, Studies with Skyhawk Therapeutics, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Skyhawk Therapeutics, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Skyhawk Therapeutics, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Skyhawk Therapeutics, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Skyhawk Therapeutics, Inc. is in.
Stories on the topics Skyhawk Therapeutics, Inc. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
ReadSearch all reports for Skyhawk Therapeutics, Inc. All companies